Galmed Pharmaceuticals Ltd. (GLMD) Stock Forecast
GLMD analyst forecast
as of October 2, 2026- Analyst consensus
- Hold 3.00 / 5 from 1 analysts
- Price target
- $12.00 average of analyst targets
- Upside to target
- +231.5% from the latest close
- Next earnings
- —
- 52-week range
- $0.47 – $4.63
GLMD analyst ratings
1 analystsNumber of analysts at each rating.
GLMD price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
GLMD earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$3.06 | −$3.06 | −$3.06 | −$2.64 | −15.9% | 1 |
| Current fiscal year (2026) | −$11.41 | −$11.41 | −$11.41 | −$19.12 | +40.3% | 1 |
| Next fiscal year (2027) | −$2.17 | −$2.17 | −$2.17 | −$11.41 | +81.0% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
GLMD revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
| Next fiscal year (2027) | $190,000 | $190,000 | $190,000 | 0.0% | 1 |
GLMD EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
GLMD revenue: reported and forecast
GLMD EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$3.12 | −$3.12 | −$3.12 | −$3.12 | −$3.06 | −1.9% | 0 up · 0 down |
| Current fiscal year (2026) | −$12.48 | −$12.48 | −$12.48 | −$12.48 | −$11.41 | −8.6% | 0 up · 1 down |
| Next fiscal year (2027) | −$7.20 | −$7.20 | −$7.20 | −$7.20 | −$2.17 | −69.9% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
GLMD earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; GLMD beat in 6 of 9.
What analysts expect from GLMD
1 analysts cover Galmed Pharmaceuticals; their consensus rating is hold (3.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $12.00, 231.5% above the latest close of $3.62. Analysts expect earnings of −$11.41 per share for 2026, +40.3% from a year earlier. For 2027 the average estimate is −$2.17 per share on revenue of $0.2 million. Galmed Pharmaceuticals beat the EPS estimate in 6 of the last 9 quarters.
Related: GLMD income statement, GLMD key metrics, GLMD chart. See the GLMD stock overview for the latest quote and news.
GLMD forecast FAQ
What is Galmed Pharmaceuticals's price target?
The average analyst price target for Galmed Pharmaceuticals is $12.00, 231.5% above the latest close of $3.62.
Is Galmed Pharmaceuticals a buy, hold or sell?
Of 1 analysts covering Galmed Pharmaceuticals, 0 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Galmed Pharmaceuticals's EPS forecast?
Analysts forecast −$11.41 per share for 2026 (range −$11.41 to −$11.41); for 2027 the estimate is −$2.17.
Does Galmed Pharmaceuticals usually beat earnings estimates?
Galmed Pharmaceuticals reported EPS at or above the analyst estimate in 6 of the last 9 quarters.